Abbott Laboratories is one of the world’s largest healthcare and medical device companies, headquartered in Abbott Park, Illinois, USA. Founded in 1888, the company operates across multiple healthcare sectors, including diagnostics, medical devices, nutrition, and branded generic pharmaceuticals.

Abbott is widely recognised for major products such as FreeStyle Libre (continuous glucose monitoring systems), cardiovascular devices, diagnostics equipment, and nutritional brands like Ensure and Pedialyte. The company has built a strong reputation through innovation in diabetes care, heart health, and laboratory diagnostics.

Currently, Abbott Laboratories’ stock is trading around $132–$133 per share. The company maintains a strong market position with a market capitalisation exceeding $230 billion. Its consistent revenue growth, global expansion, and diversified business model make it a relatively stable healthcare stock.

Abbott’s diabetes business continues to be a major growth driver, especially through strong demand for FreeStyle Libre devices worldwide. Analysts believe that if the company maintains earnings growth and expands further in medical technology, the stock could potentially target $160–$180 over the next 12–24 months.

From an investment perspective, Abbott is often considered a strong long-term stock because of its stable business model, healthcare sector resilience, and reliable dividend history. The company is also known as a Dividend King, having increased dividends for decades.

For traders, Abbott is generally considered a lower-volatility stock compared to many tech or biotech companies. This means it may be safer for conservative investors, but short-term traders may find slower price movement and fewer aggressive trading opportunities.

Overall outlook: Abbott Laboratories remains a fundamentally strong healthcare stock with long-term growth potential, dividend stability, and relatively lower risk for future investors.